Results 161 to 170 of about 8,073 (209)
International Journal of Urology, 2022 AbstractThe objective of this review study is to evaluate the therapeutic role of PDE5 inhibitors (PDE5is) in the amelioration of oligoasthenospermia in infertile males. PDE5is have a beneficial influence on the secretory function of the Leydig and Sertoli cells, the biochemical environment within the seminiferous tubule, the contractility of the ...
Fotios Dimitriadis +2 more
exaly +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The Effect of PDE5 Inhibitors on the Male Reproductive Tract
Current Pharmaceutical Design, 2021The therapeutic range of cyclic nucleotide phosphodiesterase 5 inhibitors (PDE5) inhibitors is getting wider in the last years. This review study focuses on the potential employment of PDE5 inhibitors as an adjunct tool for the therapeutic management of male infertility. The literature tends to suggest a beneficial effect of PDE5 inhibitors on Leydig
Nikolaos Sofikitis +2 more
exaly +3 more sources
Phosphodiesterase Type 5 (PDE5) Inhibitors in Erectile Dysfunction: The Proper Drug for the Proper Patient [PDF]
Journal of Sexual Medicine, 2011 Introduction. Erectile dysfunction (ED) is a very common multidimensional disorder affecting men worldwide. Physical illness, reaction to life stresses, or an unhappy couple relationship influence clinical outcome.
Giovanni Corona +2 more
exaly +4 more sources
PDE5 Inhibitors and their Applications
Current Medicinal Chemistry, 2010PDE5 belongs to a superfamily of enzymes that catalyzes the hydrolysis of cyclic nucleotides cAMP and cGMP to the corresponding 5-nucleoside monophosphate. PDE5 takes part in many physiological and pathological functions, therefore selective PDE5 inhibitors are potentially useful for a variety of pathologies.
GIOVANNONI, MARIA PAOLA +3 more
openaire +3 more sources
Journal of Urology, 2014
Metabolic syndrome (MetS) and benign prostate hyperplasia (BPH)/low urinary tract symptoms (LUTS) are often comorbid. Chronic inflammation is one of the putative links between these diseases. Phosphodiesterase type 5 inhibitors (PDE5i) are recognized as an effective treatment of BPH-related LUTS.
Linda Vignozzi +12 more
+6 more sources
Metabolic syndrome (MetS) and benign prostate hyperplasia (BPH)/low urinary tract symptoms (LUTS) are often comorbid. Chronic inflammation is one of the putative links between these diseases. Phosphodiesterase type 5 inhibitors (PDE5i) are recognized as an effective treatment of BPH-related LUTS.
Linda Vignozzi +12 more
+6 more sources
High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitors
Biochemical and Biophysical Research Communications, 2005[3H]Vardenafil (Levitra) or [3H]tadalafil (Cialis) binding was used to quantify PDE5 in rat lung and heart tissue. Each radioligand bound to purified recombinant phosphodiesterase-5 (PDE5) or to PDE5 in crude extracts with strong affinity, high specificity, slow dissociation, and good stoichiometry.
Jackie D Corbin +2 more
exaly +3 more sources
PDE5 inhibitors and pulmonary hypertension
Current Sexual Health Reports, 2008Phosphodiesterases (PDEs) are important components in cellular signaling in many vascular beds. Although the most recognized PDE inhibitor, sildenafil, a specific PDE5 inhibitor, is best known for its effect on the penile vascular bed resulting in erection, it also has therapeutic effects in other vascular beds, including the coronary and pulmonary ...
Justin S. W. Taylor, Julian P. J. Halcox
openaire +3 more sources
The efficacy and safety of PDE5 inhibitors
Clinical Cornerstone, 2005Inhibition of phosphodiesterase-5 (PDE5) reduces the degradation of cyclic guanosine monophosphate, which allows erectile function to occur by relaxation of penile smooth muscle. Three PDE5 inhibitors (sildenafil, tadalafil, and vardenafil) in a range of doses are available.
openaire +2 more sources